These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28674853)

  • 1. FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
    van de Putte EEF; Vegt E; Mertens LS; Bruining A; Hendricksen K; van der Heijden MS; Horenblas S; van Rhijn BWG
    Int Urol Nephrol; 2017 Sep; 49(9):1585-1591. PubMed ID: 28674853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
    Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pelvic Lymph Node Staging by Combined
    Pichler R; De Zordo T; Fritz J; Kroiss A; Aigner F; Heidegger I; Virgolini I; Horninger W; Uprimny C
    Clin Genitourin Cancer; 2017 Jun; 15(3):e387-e395. PubMed ID: 27601364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
    Longoni M; Scilipoti P; Re C; Rosiello G; Nocera L; Pellegrino F; Basile G; de Angelis M; Quarta L; Burgio G; Necchi A; Cigliola A; Chiti A; Picchio M; Salonia A; Briganti A; Montorsi F; Moschini M
    BJU Int; 2024 Oct; 134(4):636-643. PubMed ID: 38621771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
    Fitoussi O; Roche JB; Riviere J; Wallerand H; Poulain JE; Gordien P; Galland S; Henriques B; Dupin C; Vincent M; Kuratle T; Saffarini M; Ramos-Pascual S
    Urol Int; 2023; 107(3):239-245. PubMed ID: 36657430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete metabolic response with [
    Abrahamsson J; Kollberg P; Almquist H; Bläckberg M; Brändstedt J; Lyttkens K; Simoulis A; Sjödahl G; Sörenby A; Trägårdh E; Liedberg F
    BJU Int; 2022 Feb; 129(2):174-181. PubMed ID: 33626220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
    Moussa M; Chakra MA; Saad W; Dellis A; Papatsoris A
    Urol Oncol; 2021 Dec; 39(12):833.e9-833.e17. PubMed ID: 34059435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.
    Jeong IG; Hong S; You D; Hong JH; Ahn H; Kim CS
    Ann Surg Oncol; 2015 Sep; 22(9):3150-6. PubMed ID: 25634779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
    Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
    Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
    Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
    BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of
    Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
    Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.
    Soubra A; Hayward D; Dahm P; Goldfarb R; Froehlich J; Jha G; Konety BR
    World J Urol; 2016 Sep; 34(9):1229-37. PubMed ID: 26847182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
    Uttam M; Pravin N; Anish B; Nandita K; Arup M
    Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.
    Mertens LS; Fioole-Bruining A; van Rhijn BW; Kerst JM; Bergman AM; Vogel WV; Vegt E; Horenblas S
    J Urol; 2013 May; 189(5):1687-91. PubMed ID: 23142689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
    Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
    Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.
    Einerhand SMH; van Gennep EJ; Mertens LS; Hendricksen K; Donswijk ML; van der Poel HG; van Rhijn BWG
    Curr Opin Urol; 2020 Sep; 30(5):654-664. PubMed ID: 32701719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added Clinical Value of
    van Ginkel N; van Gennep EJ; Oosterbaan L; Greidanus J; Boellaard TN; Wondergem M; Vis AN; de Reijke TM; van Rhijn BWG; Mertens LS
    Clin Genitourin Cancer; 2023 Jun; 21(3):342-348. PubMed ID: 36918302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.